



## Asahi Kasei Pharma Corporation enters into exclusive out-license agreement for Bredinin™ in Mainland China with Lee's Pharmaceutical Holdings Limited

### Torreya advised AKP on the license agreement

Tokyo, Japan and Hong Kong, China

Lee's Pharmaceutical Holdings Limited entered into a license agreement with Asahi Kasei Pharma Corporation, a Japan-based company for the exclusive right to commercialize Bredinin™ in Mainland China.

Bredinin™ (generic name: mizoribine) was first launched in Mainland China in 1999 for the indication of suppression of rejection in renal transplantation and has already established a decent market presence within the patient population. Supplemental new drug application for lupus nephritis and nephrotic syndrome indications were submitted to China's National Medical Products Administration in June 2020.

Torreya advised Asahi Kasei Pharma Corporation on this transaction, reinforcing Torreya's strength and leadership position in China. Torreya remains the most active advisory firm in China licensing in the Life Sciences sector because of its dedicated China licensing advisory team. As a result of their deep market knowledge and strong regional relationships, Torreya has completed 15 transactions involving a China party since the beginning of 2018.

### ABOUT ASAHI KASEI PHARMA CORPORATION:

For more information about AKP, please see: [www.asahikasei-pharma.co.jp/en/](http://www.asahikasei-pharma.co.jp/en/)

### ABOUT LEE'S PHARMACEUTICAL HOLDINGS LIMITED:

For more information about Lee's Pharm, please see: [www.leespharm.com](http://www.leespharm.com)



### Deal Press Release

#### Torreya Contact

JIE LIU

Managing Director | New York Office

[jie.liu@torreya.com](mailto:jie.liu@torreya.com) | 917.683.4003 | [torreya.com](http://torreya.com)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.